Quizartinib With Azacitidine or Low-Dose Cytarabine for the Treatment of AML and MDS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Haematologica
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Phase I/II Study of the Combination of Quizartinib With Azacitidine or Low-Dose Cytarabine for the Treatment of Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Haematologica 2021 Apr 15;[EPub Ahead of Print], M Swaminathan, HM Kantarjian, M Levis, V Guerra, G Borthakur, Y Alvarado, CD DiNardo, T Kadia, G Garcia-Manero, M Ohanian, N Daver, M Konopleva, N Pemmaraju, A Ferrajoli, M Andreeff, N Jain, Z Estrov, EJ Jabbour, WG Wierda, S Pierce, MR Pinsoy, L Xiao, F Ravandi, JE CortesFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.